Clinical Trials Logo

Refractory Malignant Ascites clinical trials

View clinical trials related to Refractory Malignant Ascites.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05303844 Recruiting - Clinical trials for Refractory Malignant Ascites

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Start date: April 2, 2022
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab for patients with refractory malignant ascites.

NCT ID: NCT01852409 Recruiting - Clinical trials for Refractory Malignant Ascites

Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites

Start date: May 2013
Phase: Phase 1
Study type: Interventional

Malignant ascites often has a profound impact on the quality of life of cancer patients. Current treatments,including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Intraperitoneal bevacizumab for the palliation of malignant ascites might be a novel choice for refractory malignant ascites.